

Protocol

Immune Cell Function Assay

(20456)

Medical Benefit		Effective Date: 04/01/12	Next Review Date: 01/21
Preauthorization	No	Review Dates: 09/10, 09/11, 01/12, 01/13, 01/14, 01/15, 01/16, 01/17, 01/18, 01/19, 01/20	

This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: • With a solid organ transplant	Interventions of interest are: • Immune cell function assay with ImmuKnow	Comparators of interest are: • Standard monitoring of immunosuppression	Relevant outcomes include: • Overall survival • Test accuracy • Other test performance measures • Morbid events
Individuals: • With a hematopoietic cell transplant	Interventions of interest are: • Immune cell function assay with ImmuKnow	Comparators of interest are: • Standard of care	Relevant outcomes include: • Overall survival • Test accuracy • Other test performance measures • Morbid events
Individuals: • With a solid organ transplant	Interventions of interest are: • Immune cell function assay with Pleximmune	Comparators of interest are: • Standard monitoring of immunosuppression	Relevant outcomes include: • Overall survival • Test accuracy • Other test performance measures • Morbid events
Individuals: • With a hematopoietic cell transplant	Interventions of interest are: • Immune cell function assay Pleximmune	Comparators of interest are: • Standard of care	Relevant outcomes include: • Overall survival • Test accuracy • Other test performance measures • Morbid events

DESCRIPTION

Careful monitoring of lifelong immunosuppression is required to ensure the long-term viability of solid organ allografts without incurring an increased risk of infection. The monitoring of immunosuppression parameters attempts to balance the dual risks of rejection and infection. It is proposed that individual immune profiles, such as an immune cell function assay, will help assess the immune function of the transplant recipient and individualize immunosuppressive therapy.

SUMMARY OF EVIDENCE

For individuals who have a solid organ transplant or hematopoietic cell transplant who receive immune cell function assay testing with ImmuKnow, the evidence includes numerous studies on the association between assay test values and subsequent rejection or infection, and a randomized controlled trial in liver transplant patients. Relevant outcomes are overall survival, other test performance measures, and morbid events. The ImmuKnow test has shown variable associations with infection and rejection, depending on the type of transplant and context of the study. Across all the studies among various types of patients, ImmuKnow levels are associated with the risk of rejection when levels are high and risk of infection when levels are low. However, the absolute risk and increments of risk are uncertain because of the heterogeneity of the studies. The predictive characteristics of the test are still uncertain and do not allow a strong chain of evidence for clinical utility. The trial of the ImmuKnow test in liver transplant patients showed improvement in overall survival; however, the trial had several limitations. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have a solid organ transplant or hematopoietic cell transplant who receive immune cell function assay testing with Pleximmune, the evidence includes the U.S. Food and Drug Administration documentation and a report on the test's development and validation. Relevant outcomes are overall survival, other measures of test performance, and morbid events. Small studies have shown that Pleximmune values correlate with long-term survival. Pleximmune test results correlated with rejection, but conclusions are uncertain because of extremely limited evidence deriving from a small number of patients described briefly in the Food and Drug Administration approval documents and a second study, in which the confidence interval bounds for sensitivity and specificity estimates were wide. No direct studies of clinical utility were identified. An argument for clinical utility using a chain of evidence would rely on both a demonstration of clinical validity and a rationale that specific clinical interventions based the results of the test decrease the risk of a poor health outcome. At present, the clinical interventions that would occur as a result of the test result are uncertain, and so the clinical validity is uncertain. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

Use of the immune cell function assay to monitor and predict immune function after solid organ transplantation is considered **investigational**.

Use of the immune cell function assay to monitor and predict immune function after hematopoietic cell transplantation is considered **investigational**.

Use of the immune cell function assay for all other indications is considered **investigational**.

BACKGROUND

IMMUNOSUPPRESSION FOR TRANSPLANT

In current clinical practice, levels of immunosuppression in patients being managed after a solid organ transplant or hematopoietic cell transplantation are determined by testing for clinical toxicity (e.g., leukopenia, renal failure) and by therapeutic drug monitoring when available. However, drug levels are not a surrogate for overall drug distribution or efficacy because pharmacokinetics often differ among individuals due to clinical factors such as underlying diagnosis, age, sex, and race; circulating drug levels may not reflect the drug concentration in relevant tissues; and serum level of an individual immunosuppressant drug may not reflect the cumulative effect of other concomitant immunosuppressants. The main value of therapeutic drug monitoring is the avoidance of toxic. Individual immune profiles, such as an immune cell function assay, could support clinical decision making

and help to manage the risk of infection from excessive immunosuppression and the risk of rejection from inadequate immunosuppression.

Treatment

Several commercially available tests of immune cell function have been developed to support clinical decision making.

ImmuKnow measures the concentration of adenosine triphosphate (ATP) in whole blood after a 15- to 18-hour incubation with phytohemagglutinin (a mitogenic stimulant). Cells that respond to stimulation show increased ATP synthesis during incubation. Concurrently, whole blood is incubated in the absence of stimulant for the purpose of assessing basal ATP activity. CD4-positive T lymphocytes are immunoselected from both samples using anti-CD4 monoclonal antibody-coated magnetic particles. After washing the selected CD4-positive cells on a magnet tray, a lysis reagent is added to release intracellular ATP. A luminescence reagent added to the released ATP produces light measured by a luminometer, which is proportional to the concentration of ATP. The characterization of the cellular immune response of a specimen is made by comparing the ATP concentration for that specimen with fixed ATP production ranges.

Pleximmune measures CD154 expression on T-cytotoxic memory cells in patient's peripheral blood lymphocytes. CD154 is a marker of inflammatory response. To characterize the risk of rejection, the patient's inflammatory response to (transplant) donor cells is expressed as a fraction of the patient's inflammatory response to third-party cells. This fraction or ratio is called the Immunoreactivity Index (IR). If the donor-induced response exceeds the response to third-party cells, the individual is at increased risk for rejection. Cells are cultured and then analyzed with fluorochrome-stained antibodies to identify the cells expressing CD154. For posttransplant blood samples, an IR greater than 1.1 indicates an increased risk of rejection, and an IR less than 1.1 indicates a decreased risk of rejection. For pretransplant samples, the threshold for IR is 1.23.

REGULATORY STATUS

In April 2002, ImmuKnow® (Cylex, acquired by ViraCor-IBT Laboratories), an immune cell function assay, was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. The FDA-indicated use of ImmuKnow® is for the detection of cell-mediated immune response in populations undergoing immunosuppressive therapy for organ transplant.

In April 2002, Immune Cell Function Assay (Cylex) was cleared for marketing by FDA through the 510(k) process. The FDA-indicated use of the Immune Cell Function Assay is for the detection of cell-mediated immune response in an immunosuppressed population. In 2010, a device modification for this assay was cleared for marketing by FDA through the 510(k). There were no changes to the indications or intended use.¹

In August 2014, Pleximmune™ (Plexision) was approved by FDA through the humanitarian device exemption process.² The test is intended for use in the pretransplantation and early and late posttransplantation period in pediatric liver and small bowel transplant patients for the purpose of predicting the risk of transplant rejection within 60 days after transplantation or 60 days after sampling.

Services that are the subject of a clinical trial do not meet our Technology Assessment and Medically Necessary Services Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment and Medically Necessary Services Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced

procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Food and Drug Administration (FDA). Special 510(k): Device Modification 2010 (K101911). n.d.; https://www.accessdata.fda.gov/cdrh_docs/reviews/K101911.pdf. Accessed November 21, 2018.
2. Food and Drug Administration (FDA). Summary of Safety and Probable Benefit: Pleximmune. 2014; https://www.accessdata.fda.gov/cdrh_docs/pdf13/H130004b.pdf. Accessed November 21, 2018.
3. Ling X, Xiong J, Liang W, et al. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. *Transplantation*. Apr 15 2012;93(7):737-743. PMID 22357178
4. Rodrigo E, Lopez-Hoyos M, Corral M, et al. ImmuKnow((R)) as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: Systematic review and meta-analysis. *Liver Transpl*. Jun 27 2012;18(10):1245-1253. PMID 22740321
5. Rossano JW, Denfield SW, Kim JJ, et al. Assessment of the Cylex ImmuKnow cell function assay in pediatric heart transplant patients. *J Heart Lung Transplant*. Jan 2009;28(1):26-31. PMID 19134527
6. Wong MS, Boucek R, Kemna M, et al. Immune cell function assay in pediatric heart transplant recipients. *Pediatr Transplant*. Aug 2014;18(5):485-490. PMID 24930882
7. Ryan CM, Chaudhuri A, Concepcion W, et al. Immune cell function assay does not identify biopsy-proven pediatric renal allograft rejection or infection. *Pediatr Transplant*. Aug 2014;18(5):446-452. PMID 24930482
8. Wozniak LJ, Venick RS, Gordon Burroughs S, et al. Utility of an immune cell function assay to differentiate rejection from infectious enteritis in pediatric intestinal transplant recipients. *Clin Transplant*. Feb 2014; 28(2):229-235. PMID 24433466
9. Nishikawa K, Mizuno S, Masui S, et al. Usefulness of monitoring cell-mediated immunity for predicting post-kidney transplantation viral infection. *Transplant Proc*. Mar 2014;46(2):552-555. PMID 24656010
10. Sageshima J, Ciancio G, Chen L, et al. Lack of clinical association and effect of peripheral WBC counts on immune cell function test in kidney transplant recipients with T-cell depleting induction and steroid-sparing maintenance therapy. *Transpl Immunol*. Mar 2014;30(2-3):88-92. PMID 24518158
11. Torio A, Fernandez EJ, Montes-Ares O, et al. Lack of association of immune cell function test with rejection in kidney transplantation. *Transplant Proc*. Jul-Aug 2011;43(6):2168-2170. PMID 21839223
12. Zhou H, Wu Z, Ma L, et al. Assessing immunologic function through CD4 T-lymphocyte adenosine triphosphate levels by ImmuKnow assay in Chinese patients following renal transplantation. *Transplant Proc*. Sep 2011;43(7):2574-2578. PMID 21911125
13. Huskey J, Gralla J, Wiseman AC. Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection. *Clin J Am Soc Nephrol*. Feb 2011;6(2): 423-429. PMID 21088287
14. Reinsmoen NL, Cornett KM, Kloehn R, et al. Pretransplant donor-specific and non-specific immune parameters associated with early acute rejection. *Transplantation*. Feb 15 2008;85(3):462-470. PMID 18301338
15. Serban G, Whittaker V, Fan J, et al. Significance of immune cell function monitoring in renal transplantation after Thymoglobulin induction therapy. *Hum Immunol*. Nov 2009;70(11):882-890. PMID 19664673
16. Libri I, Gnappi E, Zanelli P, et al. Trends in immune cell function assay and donor-specific HLA antibodies in kidney transplantation: A 3-year prospective study. *Am J Transplant*. Dec 2013;13(12):3215-3222. PMID 24266972
17. Myslik F, House AA, Yanko D, et al. Preoperative Cylex assay predicts rejection risk in patients with kidney transplant. *Clin Transplant*. May 2014;28(5):606-610. PMID 24628326

18. Quaglia M, Cena T, Fenoglio R, et al. Immune function assay (immunknow) drop over first 6 months after renal transplant: a predictor of opportunistic viral infections? *Transplant Proc.* Sep 2014;46(7):2220-2223. PMID 25242755
19. Wang XZ, Jin ZK, Tian XH, et al. Increased intracellular adenosine triphosphate level as an index to predict acute rejection in kidney transplant recipients. *Transpl Immunol.* Jan 2014;30(1):18-23. PMID 24211610
20. Israeli M, Ben-Gal T, Yaari V, et al. Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests. *Transplantation.* Apr 27 2010;89(8):968-976. PMID 20075792
21. Kobashigawa JA, Kiyosaki KK, Patel JK, et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. *J Heart Lung Transplant.* May 2010;29(5):504-508. PMID 20133166
22. Gupta S, Mitchell JD, Markham DW, et al. Utility of the Cylex assay in cardiac transplant recipients. *J Heart Lung Transplant.* Aug 2008;27(8):817-822. PMID 18656792
23. Shearer GM, Clerici M. In vitro analysis of cell-mediated immunity: clinical relevance. *Clin Chem.* Nov 1994; 40(11 Pt 2):2162-2165. PMID 7955403
24. Cheng JW, Shi YH, Fan J, et al. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. *J Cancer Res Clin Oncol.* Oct 2011;137(10):1445-1453. PMID 21809031
25. Dong JY, Yin H, Li RD, et al. The relationship between adenosine triphosphate within CD4(+) T lymphocytes and acute rejection after liver transplantation. *Clin Transplant.* May-Jun 2011;25(3):E292-296. PMID 21470308
26. Hashimoto K, Miller C, Hirose K, et al. Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. *Clin Transplant.* Sep-Oct 2010;24(5):701-708. PMID 20047619
27. Cabrera R, Ararat M, Soldevila-Pico C, et al. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. *Liver Transpl.* Feb 2009;15(2):216-222. PMID 19177434
28. Jwa E, Hwang S, Kwon YJ, et al. In vitro immune cell monitoring as a guide for long-term immunosuppression in adult liver transplant recipients. *Korean J Hepatobiliary Pancreat Surg.* Nov 2015;19(4):139-148. PMID 26693232
29. Piloni D, Magni S, Oggionni T, et al. Clinical utility of CD4+ function assessment (ViraCor-IBT ImmuKnow test) in lung recipients. *Transpl Immunol.* Jul 2016;37:35-39. PMID 27095000
30. Husain S, Raza K, Pilewski JM, et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. *Transplantation.* Jun 27 2009;87(12):1852-1857. PMID 19543064
31. Bhorade SM, Janata K, Vigneswaran WT, et al. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. *J Heart Lung Transplant.* Sep 2008;27(9):990-994. PMID 18765191
32. Shino MY, Weigt SS, Saggat R, et al. Usefulness of immune monitoring in lung transplantation using adenosine triphosphate production in activated lymphocytes. *J Heart Lung Transplant.* Sep 2012;31(9):996-1002. PMID 22884386
33. Ravaioli M, Neri F, Lazzarotto T, et al. Immunosuppression modifications based on an immune response assay: results of a randomized, controlled trial. *Transplantation.* Aug 2015;99(8):1625-1632. PMID 25757214
34. Manga K, Serban G, Schwartz J, et al. Increased adenosine triphosphate production by peripheral blood CD4+ cells in patients with hematologic malignancies treated with stem cell mobilization agents. *Hum Immunol.* Jul 2010;71(7):652-658. PMID 20381567
35. Gesundheit B, Budowski E, Israeli M, et al. Assessment of CD4 T-lymphocyte reactivity by the Cylex ImmuKnow assay in patients following allogeneic hematopoietic SCT. *Bone Marrow Transplant.* Mar 2010;45(3): 527-533. PMID 19718067
36. Ashokkumar C, Talukdar A, Sun Q, et al. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. *Am J Transplant.* Jan 2009;9(1):179-191. PMID 18976293

37. Ashokkumar C, Soltys K, Mazariegos G, et al. Predicting cellular rejection with a cell-based assay: preclinical evaluation in children. *Transplantation*. Jan 2017;101(1):131-140. PMID 26950712
38. Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. *Transplantation*. Jun 2018;102(6):900-931. PMID 29596116